Propylthiouracil: Clinical Overview of its Efficacy and its Side Effects more than 50 Years after the Introduction of its Use in Thyrostatic Treatment

Abstract

This minireview gives a clinical overview of the efficacy and of the side effects of the thyrostatic drug propylthiouracil, which is in use for the treatment of Graves’ disease for more than 5 decades. It is the aim of this minireview to give convincing evidence of the value of propythiouracil in the treatment of thyrotoxic patients with Graves’ disease: The modalities of treatment are given. The advantages in comparison to methimazole are mentioned: Especially for thyrotoxic nursing mothers it represents the only thyrostatic drug approved by the American Academy of Pediatrics. Patients who experience side effects with methimazole usually can be switched successfully to propylthiouracil and vice versa. Its use for the treatment of thyrotoxicosis in pregnant women is recommended by many centres because of the comparatively little placental transfer of the drug, although the effect for the newborn does not seem to differ from that of methimazole. The minireview should remind the medical community of the value of propylthiouracil as a very valuable thyrostatic drug representing a good alternative to methimazole. It should attract interest in the drug, in spite of the fact that after 5 decades in the market there is probably only little financial profit left in selling it.

Key words

propylthiouracil - Graves' disease - toxicity

References

• 1 Abraham P, Avenell A, Park CM. et al . A systematic review of drug therapy for Graves’ hyperthyroidism.  Eur J Endocrinol. 2005;  153 489-498
• 2 American Academy of Pediatrics . Transfer of drugs and other chemicals into human milk.  Pediatrics. 2001;  108 776
• 3 Astwood EB, Sullivan J, Bisell A. et al . Action of certain sulfonamides and of thiourea upon the function of the thyroid gland of the rat.  Endocrinology. 1943;  32 210
• 4 Astwood EB. Treatment of hyperthyroidism with thiourea and thiouracil* Landmark article May 8, 1943.  JAMA. 1984;  251 1743-1746
• 5 Brent GA. Graves’ disease.  N Engl J Med. 2008;  358 2594-2605
• 6 Chattaway JM, Klepser TB. Propylthiouracil versus methimazole in treatment of Graves’ disease during pregnancy.  Ann Pharmacother. 2007;  41 1018-1022
• 7 Cooper DS. Antithyroid Drugs.  New Engl J Med. 2005;  352 905-917
• 8 Cooper DS. Treatment of thyrotoxicosis. In: Braverman LE and Utiger RD, eds. Werner & Ingbar's The Thyroid. A Fundamental and Clinical Text. 9th edition. Philadelphia; USA. Lippincott Williams & Wilkins 2005: 665-694
• 9 Cooper DS, Goldminz D, Levin AA. et al . Agranulocytosis associated with antithyroid drugs: Effects of patient age and drug dose.  Ann Intern Med. 1983;  297 26-29
• 10 Cooper DS, Saxe VC, Meskell M. et al . Acute effects of propylthiouracil (PTU) on thyroidal iodide organification and peripheral iodothyronine deiodination: correlation with serum PTU levels measured by radioimmunoassay.  J Clin Endocrinol Metab. 1982;  54 101-107
• 11 Cooper DS, Steigerwalt S, Migdal S. Pharmacology of propylthiouracil in thyrotoxicosis and chronic renal failure.  Arch Intern Med. 1987;  147 785-786
• 12 Davis LE, Lucas MJ, Hankins GD. et al . Thyrotoxicosis complicating pregnancy.  Am J Obstet Gynecol. 1989;  160 63-70
• 13 Dolman KM, Gans RO, Vervaat TJ. et al . Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy.  Lancet. 1993;  342 651-652
• 14 Gardner DF, Cruikshank DP, Hays PM. et al . Pharmacology of propylthiouracil (PTU) in pregnant hyperthyroid women: correlation of maternal PTU concentrations with cord serum thyroid function tests.  J Clin Endocrinol Metab. 1986;  62 217-220
• 15 Gotta AW, Sullivan CA, Seaman J. et al . Prolonged intraoperative bleeding caused by propylthiouracil-induced hypoprothrombinemia.  Anesthesiology. 1972;  37 562-563
• 16 Gunton JE, Stiel J, Caterson RJ. et al . Clinical case seminar: Anti-thyroid drugs and antineutrophil cytoplasmic antibody positive vasculitis. A case report and review of the literature.  J Clin Endocrinol Metab. 1999;  84 ((1)) 13-16
• 17 Gürlek A, Cobankara V, Bayraktar M. Liver tests in hyperthyroidism: effect of antithyroid therapy.  J Clin Gastroenterol. 1997;  24 180-183
• 18 Huang MJ, Li KL, Wei JS. et al . Sequential liver and bone biochemical changes in hyperthyroidism: prospective controlled follow-up study.  Am J Gastroenterol. 1994;  89 1071-1076
• 19 Kampmann JP, Hansen JM. Clincal pharmacokinetics of antithyroid drugs.  Clin Pharmacokin. 1981;  6 401-428
• 20 Kampmann JP, Johansen K, Hansen JM. et al . Propylthiouracil in human milk. Revision of a dogma.  Lancet. 1980;  1 736-737
• 21 Kitahara T, Hiromura K, Maezawa A. et al . Case of propylthiouracil-induced vasculitis associated with anti-neutrophil cytoplasmic antibody (ANCA); review of literature.  Clin Nephrol. 1997;  47 ((5)) 336-340
• 22 Liaw YF, Huang MJ, Fan KD. et al . Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study.  Ann Intern Med. 1993;  118 424-428
• 23 Mandel SJ, Cooper DS. The use of antithyroid drugs in pregnancy and lactation.  J Clin Endocrinol Metab. 2001;  86 2354-2359
• 24 Marchant B, Brownlie BE, Hart DM. et al . The placental transfer of propylthiouracil, methimazole and carbimazole.  J Clin Endocrinol Metab. 1977;  45 1187-1193
• 25 MacMurry Jr JF, Gilliland PF, Ratliff CR. et al . Pharmacodynamics of propylthiouracil in normal and hyperthyroid subjects after a single oral dose.  J Clin Endocrinol Metab. 1975;  41 362-364
• 26 Meier CA, Burger AC. Effects of drugs and other substances on thyroid hormone synthesis and metabolism. In: Braverman LE and Utiger RD, eds. Werner & Ingbar's The Thyroid. A Fundamental and Clinical Text. 9th edition. Philadelphia; USA: Lippincott Williams & Wilkins 2005: 229-246
• 27 Meyer-Gessner M, Benker G, Olbricht T. et al . Nebenwirkungen der antithyreoidalen Therapie der Hyperthyreose.  Dtsch med Wochenschr. 1989;  114 166-171
• 28 Millar LK, Wing DA, Leung AS. et al . Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism.  Obstet Gynecol. 1994;  84 946-949
• 29 Momotani N, Noh JY, Ishikawa N. et al . Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves’ Hyperthyroidism.  J Clin Endocrinol Metab. 1997;  82 3633-3636
• 30 Momotani N, Yamashita R, Makino F. et al . Thyroid function in wholly breast-feeding infants whose mothers take high doses of propylthiouracil.  Clin Endocrionol. 2000;  53 177-181
• 31 Mortimer RH, Cannell GR, Addison RS. et al . Methimazole and propylthiouracil equally cross the perfused human term placental lobule.  J Clin Endocrinol Metab. 1997;  82 3099-3102
• 32 Richter CR, Clisby KH. Toxic effects of the bitter tasting phenylthiocarbamide.  Arch Pathol. 1942;  33 46
• 33 Ross DS. Management of the various causes of thyrotoxicosis. In: Braverman LE, ed. Contemporary Endocrinology: Diseases of the Thyroid. Totowa NJ, USA: Humana Press Inc 1997: 175-198
• 34 Williams KV, Nayak S, Becker D. et al . Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned?.  J Clin Endocrinol Metab. 1997;  82 1727-1733
• 35 Zatón A, Martinez A, De Gandarias JM. The binding of thioureylene compounds to human serum albumin.  Biochem Pharmacol. 1988;  37 3127

Correspondence